Recent Progress in <i>Shigella</i> and <i>Burkholderia pseudomallei</i> Vaccines

Significant advancement has been made in the development of vaccines against bacterial pathogens. However, several roadblocks have been found during the evaluation of vaccines against intracellular bacterial pathogens. Therefore, new lessons could be learned from different vaccines developed against...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Itziar Chapartegui-González, Sarah Bowser, Alfredo G. Torres, Nittaya Khakhum
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	<i>Burkholderia pseudomallei</i> <i>Shigella</i> vaccines live attenuated glycoconjugate vaccines subunit vaccines Medicine R
Acceso en línea:	https://doaj.org/article/11685321104c405f8de3afbf71951f48
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:11685321104c405f8de3afbf71951f48
record_format	dspace
spelling	oai:doaj.org-article:11685321104c405f8de3afbf71951f482021-11-25T18:37:31ZRecent Progress in <i>Shigella</i> and <i>Burkholderia pseudomallei</i> Vaccines10.3390/pathogens101113532076-0817https://doaj.org/article/11685321104c405f8de3afbf71951f482021-10-01T00:00:00Zhttps://www.mdpi.com/2076-0817/10/11/1353https://doaj.org/toc/2076-0817Significant advancement has been made in the development of vaccines against bacterial pathogens. However, several roadblocks have been found during the evaluation of vaccines against intracellular bacterial pathogens. Therefore, new lessons could be learned from different vaccines developed against unrelated intracellular pathogens. Bacillary dysentery and melioidosis are important causes of morbidity and mortality in developing nations, which are caused by the intracellular bacteria <i>Shigella</i> and <i>Burkholderia pseudomallei</i>, respectively. Although the mechanisms of bacterial infection, dissemination, and route of infection do not provide clues about the commonalities of the pathogenic infectious processes of these bacteria, a wide variety of vaccine platforms recently evaluated suggest that in addition to the stimulation of antibodies, identifying protective antigens and inducing T cell responses are some additional required elements to induce effective protection. In this review, we perform a comparative evaluation of recent candidate vaccines used to combat these two infectious agents, emphasizing the common strategies that can help investigators advance effective and protective vaccines to clinical trials.Itziar Chapartegui-GonzálezSarah BowserAlfredo G. TorresNittaya KhakhumMDPI AGarticle<i>Burkholderia pseudomallei</i><i>Shigella</i>vaccineslive attenuatedglycoconjugate vaccinessubunit vaccinesMedicineRENPathogens, Vol 10, Iss 1353, p 1353 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	<i>Burkholderia pseudomallei</i> <i>Shigella</i> vaccines live attenuated glycoconjugate vaccines subunit vaccines Medicine R
spellingShingle	<i>Burkholderia pseudomallei</i> <i>Shigella</i> vaccines live attenuated glycoconjugate vaccines subunit vaccines Medicine R Itziar Chapartegui-González Sarah Bowser Alfredo G. Torres Nittaya Khakhum Recent Progress in <i>Shigella</i> and <i>Burkholderia pseudomallei</i> Vaccines
description	Significant advancement has been made in the development of vaccines against bacterial pathogens. However, several roadblocks have been found during the evaluation of vaccines against intracellular bacterial pathogens. Therefore, new lessons could be learned from different vaccines developed against unrelated intracellular pathogens. Bacillary dysentery and melioidosis are important causes of morbidity and mortality in developing nations, which are caused by the intracellular bacteria <i>Shigella</i> and <i>Burkholderia pseudomallei</i>, respectively. Although the mechanisms of bacterial infection, dissemination, and route of infection do not provide clues about the commonalities of the pathogenic infectious processes of these bacteria, a wide variety of vaccine platforms recently evaluated suggest that in addition to the stimulation of antibodies, identifying protective antigens and inducing T cell responses are some additional required elements to induce effective protection. In this review, we perform a comparative evaluation of recent candidate vaccines used to combat these two infectious agents, emphasizing the common strategies that can help investigators advance effective and protective vaccines to clinical trials.
format	article
author	Itziar Chapartegui-González Sarah Bowser Alfredo G. Torres Nittaya Khakhum
author_facet	Itziar Chapartegui-González Sarah Bowser Alfredo G. Torres Nittaya Khakhum
author_sort	Itziar Chapartegui-González
title	Recent Progress in <i>Shigella</i> and <i>Burkholderia pseudomallei</i> Vaccines
title_short	Recent Progress in <i>Shigella</i> and <i>Burkholderia pseudomallei</i> Vaccines
title_full	Recent Progress in <i>Shigella</i> and <i>Burkholderia pseudomallei</i> Vaccines
title_fullStr	Recent Progress in <i>Shigella</i> and <i>Burkholderia pseudomallei</i> Vaccines
title_full_unstemmed	Recent Progress in <i>Shigella</i> and <i>Burkholderia pseudomallei</i> Vaccines
title_sort	recent progress in <i>shigella</i> and <i>burkholderia pseudomallei</i> vaccines
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/11685321104c405f8de3afbf71951f48
work_keys_str_mv	AT itziarchaparteguigonzalez recentprogressinishigellaiandiburkholderiapseudomalleiivaccines AT sarahbowser recentprogressinishigellaiandiburkholderiapseudomalleiivaccines AT alfredogtorres recentprogressinishigellaiandiburkholderiapseudomalleiivaccines AT nittayakhakhum recentprogressinishigellaiandiburkholderiapseudomalleiivaccines
_version_	1718410876611985408

Recent Progress in <i>Shigella</i> and <i>Burkholderia pseudomallei</i> Vaccines

Ejemplares similares